Trial Profile
A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS 5461 in Subjects With Hepatic Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Feb 2016
Price :
$35
*
At a glance
- Drugs Buprenorphine/samidorphan (Primary)
- Indications Liver disorders
- Focus Pharmacokinetics
- Sponsors Alkermes
- 03 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 May 2015 New trial record